China Biologic Products (NASDAQ:CBPO) was downgraded by stock analysts at Credit Suisse Group from an “outperform” rating to a “neutral” rating in a note issued to investors on Monday.
A number of other brokerages have also recently issued reports on CBPO. Zacks Investment Research raised China Biologic Products from a “sell” rating to a “hold” rating in a research report on Tuesday, July 17th. ValuEngine raised China Biologic Products from a “sell” rating to a “hold” rating in a research report on Tuesday, July 10th. BidaskClub raised China Biologic Products from a “sell” rating to a “hold” rating in a research report on Thursday, May 31st. Finally, Jefferies Financial Group cut China Biologic Products from a “buy” rating to a “hold” rating in a research report on Monday, May 14th. Five analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. China Biologic Products has a consensus rating of “Hold” and a consensus target price of $101.00.
China Biologic Products traded down $6.89, hitting $93.13, during trading hours on Monday, according to Marketbeat.com. 10,853 shares of the company were exchanged, compared to its average volume of 374,685. China Biologic Products has a 52-week low of $71.85 and a 52-week high of $107.44. The company has a market cap of $3.31 billion, a price-to-earnings ratio of 18.98, a price-to-earnings-growth ratio of 1.63 and a beta of 1.36.
China Biologic Products (NASDAQ:CBPO) last released its quarterly earnings data on Friday, August 3rd. The biopharmaceutical company reported $1.17 EPS for the quarter, missing analysts’ consensus estimates of $1.26 by ($0.09). China Biologic Products had a net margin of 17.76% and a return on equity of 17.29%. The business had revenue of $120.40 million during the quarter, compared to analysts’ expectations of $116.21 million. During the same quarter in the previous year, the company posted $1.35 EPS. The company’s revenue was up 34.8% compared to the same quarter last year. analysts anticipate that China Biologic Products will post 4.71 EPS for the current year.
Institutional investors have recently bought and sold shares of the business. Parametrica Management Ltd acquired a new stake in China Biologic Products during the 2nd quarter worth approximately $386,000. Kassirer Asset Management Corp acquired a new stake in China Biologic Products during the 2nd quarter worth approximately $596,000. Geode Capital Management LLC acquired a new stake in China Biologic Products during the 4th quarter worth approximately $1,375,000. Comerica Bank lifted its position in China Biologic Products by 34.1% during the 1st quarter. Comerica Bank now owns 16,733 shares of the biopharmaceutical company’s stock worth $1,458,000 after acquiring an additional 4,256 shares during the period. Finally, Azimuth Capital Management LLC lifted its position in China Biologic Products by 13.8% during the 1st quarter. Azimuth Capital Management LLC now owns 20,375 shares of the biopharmaceutical company’s stock worth $1,650,000 after acquiring an additional 2,470 shares during the period. 54.34% of the stock is owned by institutional investors.
China Biologic Products Company Profile
China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.
Recommended Story: Market Capitalization – What it Means for Investors
Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.